Head-to-head evidence
ABBV-RGX-314 vs HLX04-O
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
ABBV-RGX-314
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
HLX04-O
Developed by Shanghai Henlius Biotech
NCT04740671 · Phase 3 · completed
The trial randomized 410 participants to HLX04-O or the active comparator ranibizumab and masked both participants and investigators. Its primary clinical endpoint was the mean change in best-corrected visual acuity at Week 36, but no statistical comparison or outcome result is available yet.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-RGX-314's landscape · HLX04-O's landscape